Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Inventiva
  6. News
  7. Summary
    IVA   FR0013233012


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inventiva : Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

07/20/2021 | 04:02am EDT


Half-Year Review of Inventiva's Liquidity Contract with


Kepler Cheuvreux

Daix (France), July 9, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2021:

Cash: € 689,129.05

Number of shares: 46,603

At the last half-year report as of December 31, 2020, the following resources were available in the liquidity account:

Cash: € 1,028,694.86

Number of shares: 15,493

When the contract was initially implemented, the following resources were included in the liquidity account:

Cash: € 163,510.42

Number of shares: 34,063

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV-157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration



enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA -

ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com



Brunswick Group

Westwicke, an ICR Company

Pascaline Clerc

Yannick Tetzlaff /

Patricia L. Bank

VP of Global External Affairs

Tristan Roquet Montegon /

Investor relations


Aude Lepreux


+1 240 620 9175

Media relations

+1 415 513 1284


+33 1 53 96 83 83

Important Notice

This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva's clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, or that candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current



COVID-19 pandemic. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2020 filed with the Autorité des Marchés Financiers on March 15, 2021, the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 15, 2021 as well as the full-year financial report for the year ended December 31, 2020 for additional information in relation to such factors, risks and uncertainties.

Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward- looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.



Inventiva SA published this content on 20 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2021 08:01:07 UTC.

ę Publicnow 2021
All news about INVENTIVA
09/23INVENTIVA : Concludes $30 Million Sale of American Depositary Shares
09/23INVENTIVA : completes sale of $30 million through its ATM program to existing and new spec..
09/22INVENTIVA S A : HC Wainwright Lifts Price Target on Inventiva to $40 From $38, Maintains B..
09/22INVENTIVA : US FDA Widens Fast Track Designation For Inventiva's Liver Disease Therapy
09/21INVENTIVA : announces FDA decision that Fast Track designation granted to lanifibranor in ..
09/21INVENTIVA S A : Says FDA's Fast-Track Designation for Lanifibranor Includes Treatment of N..
09/21INVENTIVA : announces FDA decision that Fast Track designation granted to lanifibranor in ..
09/20INVENTIVA : H1 2021 financial results and corporate update
09/20INVENTIVA : Interim Financial Report for the Six Months Ended June 30, 2021 (Form 6-K)
09/20Inventiva S.A. Announces Consolidated Unaudited Earnings Results for the Second Quarter..
More news
Analyst Recommendations on INVENTIVA
More recommendations
Sales 2021 3,93 M 4,61 M 4,61 M
Net income 2021 -51,6 M -60,5 M -60,5 M
Net cash 2021 47,3 M 55,4 M 55,4 M
P/E ratio 2021 -9,14x
Yield 2021 -
Capitalization 468 M 548 M 549 M
EV / Sales 2021 107x
EV / Sales 2022 275x
Nbr of Employees 100
Free-Float 72,6%
Duration : Period :
Inventiva Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 7
Last Close Price 12,12 €
Average target price 27,23 €
Spread / Average Target 125%
EPS Revisions
Managers and Directors
FrÚdÚric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial & Administrative Officer
Pierre Broqua Director, Deputy CEO & Chief Scientific Officer
Michael P. Cooreman Chief Medical Officer
Alice Roudot-Ketelers Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685